Aim: To evaluate safety and efficacy of Laser in situ Keratomileusis (LASIK) procedure for the correction of high hypermetropia. Methods: Retrospective study of 160 patients (266 eyes) who underwent LASIK procedure for the correction of hypermetropia between +3.00 and +7.00 diopters(D) and cylinder up to 2.00D from January 2013 and August 2015. All ablations were performed with Wavelight Allegretto Eye-Q400Hzexcimer laser (Alcon, Forth Worth, TX, USA) with aberration free module and were centered on a corneal vertex. All flaps were made with Moria M2 (Moria, Antony, France) mechanical microkeratome (90µm head). Preoperative and postoperative uncorrected and corrected distant visual acuity (UDVA, CDVA), spherical equivalent (SE) and a berrometry for 5mm pupil were measured. Measurements were taken at 1 week, 1,3,6 and 12 months after the surgery. Wilcoxon Signed Ranks Test was used for statistical analysis.
INTRODUCTION
Refractive surgery for hyperopia has been a challenge for surgeons in last few decades (1, 2) . Hyperopia contributes to around 1/3 of all of refractive anomalies (3), but still the focus of corneal refractive surgery has centered primarily on myopia. Many studies have reported high level of safety and efficacy of Laser in situ Keratomileusis (LASIK) in correction of low hyperopia(up to 4 D) (1) (2) (4) (5) .
The complications that have been limiting hyperopic LASIK in high hyperopia include decentration and regression, poor qualityof vision related to the induction of a significant high level of higher-order aberrations which can affect the predictability, safety, and efficacy of the treatment (6) (7) (8) .
However, advances in eye trackers and ablation profiles have led to improvement in results of LASIK even for high hyperopia (4-5, 9-12).
AIM
The purpose of this study is to evaluate safety and efficacy of LASIK procedure in high hyperopia.
METHODS
The study included 160 patients (266 eyes) that underwent LASIK procedure for hypermetropia correction. The range of diopters was between +3.00 and +7.0 diopters(D) and cylinder up to 2.00 D.
Preoperative examinations All patients underwent a complete preoperative ophthalmological examination. Inclusion criteria were: stable refraction, hypermetropia between +3.00 and +7.00 D, astigmatism ≤2.00 D. Ocular criteria were those normally adopted in refractive surgery. Exclusion criteria were unstable hyperopia, age younger than 18 years, active corneal disease, lens opacities, irregular cornea on corneal topography, previous ocular surgery, history of ocular trauma, ORIGINAL PAPER uveitis, anterior or posterior synechiae, glaucoma, and ocular hypertension. Patients with amblyopia and a potential CDVA of less than 0.2 were also excluded.
Surgical procedure and postoperative care
Prior to the surgery, two drops of topical anesthetic (Novesine, OmniVision GmbH, Puchheim, Germany) were instilled at 2-minute intervals, and the eye was cleaned with 2.5 % povidone iodine. A corneal flap was made using Moria M2 mechanical microkeratome with 90 μm head (Moria, Antony, France). Wavelight Allegretto Eye-Q 400Hz (Alcon, Forth Worth, TX, USA) was used for the excimer laser treatment. The optical zone was fixed at 6.5 mm as recommended by the manufacturer, and the wave front optimized program was used. The Aberration FreeTM program was applied in all cases.
For all patients, the programmed treatment consisted of cycloplegic spherical correction with manifest astigmatic power and axis. "Wellington nomogram" provided by the company was used for spherical correction.
The flap was lifted and excimer laser ablation was delivered to the stroma. Patients were instructed to concentrate on the fixation light throughout the ablation. When the ablation was completed, the flap was repositioned after the interface was irrigated with balanced salt solution, removing any debris. Postoperative therapy included combination of topical antibiotic and steroid drops (Tobradex, Alcon, Forth Worth, TX, USA) 4 times daily for 2 weeks, and artificial tears (Blink, Abbott Medical Optics, Santa Ana, CA, USA) 6-8 times daily for at least 1 month.
Postoperative evaluation All patients were examined at 1 week, 1, 3, 6 and 12 months after the surgery. Results 1 year after the surgery were analyzed in this study. At each visit UDVA, CDVA and SE were measured. Slit-lamp examination, tonometry, and corneal topography was also performed.
Statistical calculation was performed with SPSS for Windows (19.0, SPSS Inc, Chicago, Illinois, SAD) and Microsoft Excel (11.0, Microsoft Corporation, Redmond, WA, SAD). The comparison between the preoperative and postoperative periods was performed with the Wilcoxon signed rank test. Value of p<0.05 was considered statistically significant.
RESULTS
The study has been conducted from January 2013 and August 2015. Out of 160 patients (266 eyes) 93 were males (58%) and 67 were females (42%). Average age was 42±11.3 years (range: 21 -66 years).
CDVA preoperatively was 0.77±0.24 (range: 0.6-0.9). Postoperative UDVA was lower than preoperative CDVA at 1 week (p=0.001), at 1 month there was no difference (p=0.099), but at 3,6 and 12 months UDVA was significantly better compared to preoperative CDVA (p<0.0001).
Preoperative SE was 4.69±1.2D (range +3.75 to +7.50 D). At 1 week SE was 0.03±0.67D (range -0.50 to + 0.63D), while at 1 year regressed to 0.58±0.56D (range +0.25 to +0.88D), as shown in Graph 1. Sphere shifted from negative values targeted in treatment planning to compensate for regression to positive values. There was significant difference in SE at every time point (p<0.0005). There was a strong correlation between the attempted and achieved corrections (R2 Z 0.65). (Graph 2).
There was no statistically significant difference in postoperative values of keratometry and pachymetry during follow up period. In Graph 3 keratometry changes are presents.
There was a significant increase in coma (p<0.0001), trefoil (p<0.0001, p=0.0006) and spherical aberration (p=0.022, p=0.0052) at 1 week and 1 month postoperatively, without change throughout the rest of follow up. In our study efficacy index (defined as UDVA at 12 month postoperatively / CDVA preoperatively) 1.037. Safety index (defined as CDVA at 12 months / CDVA preoperatively) 1.054.
DISCUSSION
For few decades there have been many attempts to correct hyperopia, but were not effective or safe enough (9, 13) . Recent literature on the other hand shows that it is possible to achieve±0.50D one year after LASIK in hyperopic patients, which is also demonstrated in our study (14) . Result of our study do differ somewhat from current literature. Residual SE in our study was as high as +0.40 D. Kanellopulus et al. report residual myopia of -0.39±0.30D after two years, and Gil-Cazora et al. hyperopia of +0.72±0.80D in first months after the surgery (15, 16) . In our study there was small myopic shift (p<0.001) in first postoperative visits, but this slight over correction was transitory. This can also be consistent with the natural progression of hyperopia in population (17) . Desai et al. reported modest regression of refractive effect even after 5 years of followup (+0.40 ± 0.79 D) (18) . Other older publications stated that under correction was expected in patients with SE +5.00 D. Those results were guidelines for better planning, so this over correction in first postoperative period was expected and planned (19) .
Complications in this study were loss of 2 lines in twoeyes (0.74%), loss of 1 line in one eye (0.37%), diffuse lamellar keratitis (DLK) in three eyes (1.13%), prolonged dry eye in nine patients (18 eyes) (6.7%) even after 3 months postoperatively. Loss of lines varies between studies (18, 19) , older studies state that the higher hyperopia and the smaller optical zone, loss of lines and less efficient results are expected (7) . Later, surgical safety was defined as loss of 2 or more lines of CDVA at 6 months between 1 and 5% (21).Our study is within these margins.
There was a significant increase in coma (p<0.0001), trefoil (p<0.0001, p=0.0006) and spherical aberration (p=0.022, p=0.0052) at 1 week and 1 month postoperatively, without change throughout the rest of follow up.
Increase in coma and spherical aberration was statistically significant, similar results have been reported by other authors (22) . Induction of HOAs in our patients can have correlation to loss of lines in the study, but there was not statistically significant connection. Further, more HOA oriented studies, are needed to include more factors into study.
Enhancement was performed in 15 eyes (5.6%), compared to 29.4% reported by Jorge L et al (23) . We believe that our low percent of enhancement is due to newer eye tracking systems, balanced nomograms and higher repletion rate of laser and the use of optimized aberration-free ablation profiles. Also, we have rigorous inclusion criteria in terms of full cyclopegia and long preoperative preparation with the patient.
Safety index is somewhat higher compared to Jorge (index 0.94), in our study index was 1.054. Efficacy index on the other hand was extremely better (index 1.037), than in other studies: (ranging from 0.6115 to 0.9) (24). Our results were morecomparable to Simon et al. report ofsafety index 1.03 and efficacy index 1.40 (25) .
We plan to report the outcomes over a longer period, because some studies found average increase in hyperopia +0,54 over 5 years postoperatively, which is more than expected physiologically and can be indicator of destabilization of cornea after LASIK (20).
CONCLUSION
LASIK for high hyperopia showed satisfactory results in postoperative refraction with reasonable regression without loss of lines of visual acuity, however more test are necessary to asses optical quality.
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